Literature DB >> 34166680

The role of PD-1/PD-L1 checkpoint in arsenic lung tumorigenesis.

Wenhua Xu1, Jiajun Cui2, Linqing Wu3, Caigu He4, Gang Chen5.   

Abstract

Chronic exposure to environmental arsenic promotes lung cancer. Emerging evidence indicates that compromised host immunity, particularly T cell anti-tumor immunity, may play a critical role in cancer development. However, there is a knowledge gap in terms of the effects of arsenic exposure on T cell anti-tumor immunity and how that may contribute to arsenic lung carcinogenicity. Immunosuppression has been known as a risk factor for many types of cancer, including lung cancer. The development of cancer indicates the success of immunosuppression and escape of cancer cells from host anti-tumor immunity in which T cells are the major component. The anti-tumor immunity is mainly executed by CD8 cytotoxic T cells through their anti-tumor effector function, which can be regulated by immune checkpoint pathways. Some inhibitory receptors on the T cell membrane and their ligands form these pathways, among which programmed death-1 (PD-1), a T cell inhibitory receptor, and its ligand, programmed death-ligand 1 (PD-L1), are best characterized. A/J mice are naturally sensitive to pulmonary carcinogens, prone to develop spontaneous lung tumors later in life and have been frequently used as an animal model for lung tumorigenesis research. Chronic arsenic administration through drinking water has been shown to enhance tumor formation in the lungs of A/J mice. In the current study, using this mouse model we want to determine whether PD-1/PD-L1 plays a role in arsenic-enhanced lung tumorigenesis. The results showed that prolonged arsenic exposure up-regulated PD-1/PD-L1, increased regulatory T cells (Tregs), decreased CD8/Treg ratio, inhibited T cell antitumor function in the lungs and enhanced lung tumor formation, while inhibition of PD-1/PD-L1 restored CD8/Treg ratio and T cell anti-tumor effector function, and mitigated arsenic-enhanced lung tumorigenesis. In addition, inhibition of PD-1/PD-L1 could be a potential preventive strategy to mitigate the tumorigenic action of chronic arsenic exposure.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Arsenic; Lung; PD-1; PD-L1; T cell; Tumor

Mesh:

Substances:

Year:  2021        PMID: 34166680      PMCID: PMC8338898          DOI: 10.1016/j.taap.2021.115633

Source DB:  PubMed          Journal:  Toxicol Appl Pharmacol        ISSN: 0041-008X            Impact factor:   4.460


  42 in total

1.  The chi-square test and accompanying effect size indices.

Authors:  Jeffrey A Gliner; George A Morgan; Robert J Harmon
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2002-12       Impact factor: 8.829

2.  Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice.

Authors:  Liufu Deng; Hua Liang; Byron Burnette; Michael Beckett; Thomas Darga; Ralph R Weichselbaum; Yang-Xin Fu
Journal:  J Clin Invest       Date:  2014-01-02       Impact factor: 14.808

3.  Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors.

Authors:  Esra A Akbay; Shohei Koyama; Julian Carretero; Abigail Altabef; Jeremy H Tchaicha; Camilla L Christensen; Oliver R Mikse; Andrew D Cherniack; Ellen M Beauchamp; Trevor J Pugh; Matthew D Wilkerson; Peter E Fecci; Mohit Butaney; Jacob B Reibel; Margaret Soucheray; Travis J Cohoon; Pasi A Janne; Matthew Meyerson; D Neil Hayes; Geoffrey I Shapiro; Takeshi Shimamura; Lynette M Sholl; Scott J Rodig; Gordon J Freeman; Peter S Hammerman; Glenn Dranoff; Kwok-Kin Wong
Journal:  Cancer Discov       Date:  2013-09-27       Impact factor: 39.397

4.  Assessing symmetry of zygomatic bone through three-dimensional segmentation on computed tomography scan and "mirroring" procedure: A contribution for reconstructive maxillofacial surgery.

Authors:  Daniele Gibelli; Michaela Cellina; Stefano Gibelli; Antonio Giancarlo Oliva; Giovanni Termine; Valentina Pucciarelli; Claudia Dolci; Chiarella Sforza
Journal:  J Craniomaxillofac Surg       Date:  2018-02-22       Impact factor: 2.078

Review 5.  T-cell exhaustion in the tumor microenvironment.

Authors:  Y Jiang; Y Li; B Zhu
Journal:  Cell Death Dis       Date:  2015-06-18       Impact factor: 8.469

6.  Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression.

Authors:  Limo Chen; Don L Gibbons; Sangeeta Goswami; Maria Angelica Cortez; Young-Ho Ahn; Lauren A Byers; Xuejun Zhang; Xiaohui Yi; David Dwyer; Wei Lin; Lixia Diao; Jing Wang; Jonathon Roybal; Mayuri Patel; Christin Ungewiss; David Peng; Scott Antonia; Melanie Mediavilla-Varela; Gordon Robertson; Milind Suraokar; James W Welsh; Baruch Erez; Ignacio I Wistuba; Lieping Chen; Di Peng; Shanshan Wang; Stephen E Ullrich; John V Heymach; Jonathan M Kurie; F Xiao-Feng Qin
Journal:  Nat Commun       Date:  2014-10-28       Impact factor: 14.919

Review 7.  What does PD-L1 positive or negative mean?

Authors:  Antoni Ribas; Siwen Hu-Lieskovan
Journal:  J Exp Med       Date:  2016-11-30       Impact factor: 14.307

8.  Establishment of the Reference Intervals of Lymphocyte Function in Healthy Adults Based on IFN-γ Secretion Assay upon Phorbol-12-Myristate-13-Acetate/Ionomycin Stimulation.

Authors:  Hongyan Hou; Yu Zhou; Jing Yu; Lie Mao; Munyemana Jean Bosco; Juan Wang; Yanfang Lu; Liyan Mao; Xiaohui Wu; Feng Wang; Ziyong Sun
Journal:  Front Immunol       Date:  2018-02-07       Impact factor: 7.561

9.  Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors.

Authors:  Frederick Arce Vargas; Andrew J S Furness; Isabelle Solomon; Kroopa Joshi; Leila Mekkaoui; Marta H Lesko; Enrique Miranda Rota; Rony Dahan; Andrew Georgiou; Anna Sledzinska; Assma Ben Aissa; Dafne Franz; Mariana Werner Sunderland; Yien Ning Sophia Wong; Jake Y Henry; Tim O'Brien; David Nicol; Ben Challacombe; Stephen A Beers; Samra Turajlic; Martin Gore; James Larkin; Charles Swanton; Kerry A Chester; Martin Pule; Jeffrey V Ravetch; Teresa Marafioti; Karl S Peggs; Sergio A Quezada
Journal:  Immunity       Date:  2017-04-11       Impact factor: 31.745

Review 10.  Sex Differences in Cancer Immunotherapy Efficacy, Biomarkers, and Therapeutic Strategy.

Authors:  Shixiang Wang; Li An Cowley; Xue-Song Liu
Journal:  Molecules       Date:  2019-09-04       Impact factor: 4.411

View more
  1 in total

1.  Ethanol Exposure Up-Regulates PD-L1/PD-1 Immune Checkpoint Pathway and Promotes Mammary Tumor Development.

Authors:  Wenhua Xu; Linqing Wu; Mei Xu; Jia Luo; Gang Chen
Journal:  Front Oncol       Date:  2022-06-08       Impact factor: 5.738

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.